Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

08. April 2021 09:30 ET | Quelle: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen under FDA’s Expanded Access Pathway

SEATTLE, April 08, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
11. März 2021 09:30 ET | Quelle: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Receipt of FDA Safe to Proceed Letter for Treatment of an Ovarian Cancer Patient with Oral Endoxifen Under Expanded Access Pathway

SEATTLE, March 11, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
03. Februar 2021 09:30 ET | Quelle: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Two-Year Update of FDA-Approved Expanded Access Treatment with Endoxifen

SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
30. Juli 2020 09:30 ET | Quelle: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Findings from FDA-Approved Expanded Access Treatment with Endoxifen

SEATTLE, July 30, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...